Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 1/20 | 0.33 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.33 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.30 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16946794 | 0.84 | RBP4 (0.34) | RBP4KAT6AKAT5PDK2P2RX3 | |
| SCHEMBL16946750 | 0.82 | NTRK1 (0.37) | RBP4PDK2P2RX3NTRK1NTRK3 | |
| SCHEMBL16947088 | 0.78 | RBP4 (0.39) | RBP4NTRK1NTRK3NTRK2 | |
| SCHEMBL18353076 | 0.76 | AAK1 (0.37) | RBP4KAT6AKAT5PDK2ALK | |
| SCHEMBL16947094 | 0.76 | AAK1 (0.37) | RBP4KAT6AKAT5PDK2ALK | |
| SCHEMBL16946700 | 0.75 | PDK2 (0.43) | RBP4KAT6AKAT5PDK2HTR2A | |
| SCHEMBL19631449 | 0.71 | AAK1 (0.34) | RBP4 | |
| SCHEMBL21601459 | 0.69 | PDK2 (0.47) | RBP4PDK2HTR2AHTR2CSLC6A4 | |
| SCHEMBL20903440 | 0.69 | RBP4 (0.36) | RBP4KAT6AKAT5PDK2HTR2A | |
| SCHEMBL21941201 | 0.68 | PDK2 (0.33) | RBP4KAT6AKAT5PDK2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9714258-B2 | Diaryl macrocycles as modulators of protein kinases | TP THERAPEUTICS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20170002023-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TP THERAPEUTICS, INC. (US) | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002023-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | MAP3K20, LCK, MAP3K1 | RBP4 4739/4885KAT6A 2135/4885KAT5 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.